PubMed:18657193 JSON TXT

Annnotations TAB JSON ListView MergeView

c_corpus

UseCases_ArguminSci_Discourse

{"project":"UseCases_ArguminSci_Discourse","denotations":[{"id":"T1","span":{"begin":0,"end":149},"obj":"DRI_Background"},{"id":"T2","span":{"begin":162,"end":581},"obj":"DRI_Approach"},{"id":"T3","span":{"begin":582,"end":770},"obj":"DRI_Background"},{"id":"T4","span":{"begin":780,"end":831},"obj":"DRI_Unspecified"},{"id":"T5","span":{"begin":832,"end":918},"obj":"DRI_Background"},{"id":"T6","span":{"begin":919,"end":1073},"obj":"DRI_Outcome"},{"id":"T7","span":{"begin":1074,"end":1171},"obj":"DRI_Background"},{"id":"T8","span":{"begin":1172,"end":1339},"obj":"DRI_Background"},{"id":"T9","span":{"begin":1340,"end":1390},"obj":"DRI_Background"},{"id":"T10","span":{"begin":1391,"end":1503},"obj":"DRI_Approach"},{"id":"T11","span":{"begin":1504,"end":1590},"obj":"DRI_Approach"},{"id":"T12","span":{"begin":1591,"end":1735},"obj":"DRI_Outcome"},{"id":"T13","span":{"begin":1749,"end":1867},"obj":"DRI_Background"}],"text":"Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases.\nUNLABELLED: Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T \u0026 Katoh R (2008) Histopathology53, 288-298Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast - comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases Aims: To clarify the clinicopathological significance of breast neuroendocrine ductal carcinoma in situ (NE-DCIS), i.e. DCIS in which \u003e50% of cells immunohistochemically express NE markers (chromogranin A and/or synaptophysin), 20 NE-DCIS were studied and the findings compared with those of 274 non-NE-DCIS.\nMETHODS AND RESULTS: NE-DCIS accounted for 6.8% of all DCIS. Mean patient age was 50.4 years for NE-DCIS and 49.6 years for non-NE-DCIS (P = 0.66). The main clinical presentation of NE-DCIS was a bloody nipple discharge, seen in 72%, significantly different from the 5% in non-NE-DCIS cases (P \u003c 0.01). Carcinoma was preoperatively diagnosed in 67% of NE-DCIS and 95% of non-NE-DCIS cases (P \u003c 0.01). NE-DCIS was histologically characterized by a predominantly solid growth of cancer cells with fine-granular cytoplasm and ovoid, or occasionally spindle-shaped nuclei. A well-developed vascular network was also common. Nuclear grades and Van Nuys classification were significantly lower for NE-DCIS than for non-NE-DCIS (P \u003c 0.01). The mean MIB-1 labelling index was 4.3% in NE-DCIS and 8.1% in non-NE-DCIS (P \u003c 0.01). Furthermore, NE-DCIS cases had significantly higher oestrogen and progesterone receptor and lower HER2 scores than non-NE-DCIS cases (P \u003c 0.01).\nCONCLUSIONS: NE-DCIS has characteristic clinicopathological features and can, therefore, be regarded as a distinct variant of DCIS."}

PubMed_Structured_Abstracts

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T1","span":{"begin":162,"end":770},"obj":"UNLABELLED"},{"id":"T2","span":{"begin":792,"end":1735},"obj":"RESULTS"},{"id":"T3","span":{"begin":1749,"end":1867},"obj":"CONCLUSIONS"}],"text":"Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases.\nUNLABELLED: Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T \u0026 Katoh R (2008) Histopathology53, 288-298Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast - comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases Aims: To clarify the clinicopathological significance of breast neuroendocrine ductal carcinoma in situ (NE-DCIS), i.e. DCIS in which \u003e50% of cells immunohistochemically express NE markers (chromogranin A and/or synaptophysin), 20 NE-DCIS were studied and the findings compared with those of 274 non-NE-DCIS.\nMETHODS AND RESULTS: NE-DCIS accounted for 6.8% of all DCIS. Mean patient age was 50.4 years for NE-DCIS and 49.6 years for non-NE-DCIS (P = 0.66). The main clinical presentation of NE-DCIS was a bloody nipple discharge, seen in 72%, significantly different from the 5% in non-NE-DCIS cases (P \u003c 0.01). Carcinoma was preoperatively diagnosed in 67% of NE-DCIS and 95% of non-NE-DCIS cases (P \u003c 0.01). NE-DCIS was histologically characterized by a predominantly solid growth of cancer cells with fine-granular cytoplasm and ovoid, or occasionally spindle-shaped nuclei. A well-developed vascular network was also common. Nuclear grades and Van Nuys classification were significantly lower for NE-DCIS than for non-NE-DCIS (P \u003c 0.01). The mean MIB-1 labelling index was 4.3% in NE-DCIS and 8.1% in non-NE-DCIS (P \u003c 0.01). Furthermore, NE-DCIS cases had significantly higher oestrogen and progesterone receptor and lower HER2 scores than non-NE-DCIS cases (P \u003c 0.01).\nCONCLUSIONS: NE-DCIS has characteristic clinicopathological features and can, therefore, be regarded as a distinct variant of DCIS."}

PubMed:18657193 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

UseCases_ArguminSci_Discourse

PubMed_Structured_Abstracts

PubMed:18657193 JSON TXT